On October 30, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences (Press release, Kura Oncology, OCT 30, 2023, View Source [SID1234636445]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A virtual fireside chat at the TD Cowen Fall Oncology Innovation Summit: Insights for SITC (Free SITC Whitepaper) and ASH (Free ASH Whitepaper) event at 12:00 p.m. ET / 9:00 a.m. PT on November 3, 2023;
A fireside chat at the Stifel 2023 Healthcare Conference in New York at 11:30 a.m. ET / 8:30 a.m. PT on November 14, 2023; and
A fireside chat at the Jefferies London Healthcare Conference in London at 9:30 a.m. GMT / 5:30 a.m. ET / 2:30 a.m. PT on November 16, 2023.

Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following all three events.